DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |


Parse error: syntax error, unexpected '/' in /homepages/1/d315158125/htdocs/Pharmaclient/biotech/fonctions.inc(162) : eval()'d code on line 6
$texte= " * INDICIA BIOTECHNOLOGY *


 

1998 - Rhône-Alpes
Lyon
www.indicia.fr

 

Contract, Research
Key words: Microparticle technology, Immunoassay, Reagents, Luminex, OEM dosing methods, OEM production services
Mission: to provide third parties with solutions in R&D and manufacturing by providing a complete range of comprehensive services in the areas of immuno-diagnostics, microbiology and sterile reagents
Clients: Pharmaceutical industry, Diagnostics industry
infos@indicia.fr

Age: " . AGE() . " year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Legastelois (Stéphane) [born 1960, Ph.D. biochemistry, ex-Merck KgAa, Indicia Diagnostics]
Oper.Dir.-COO: Panier (Elodie) [Ms.Sc., Eng. IUP, DESS Management]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2010 = 0.51 M€)
Note : initial company registering under Indicia: 1984.03

Turnover (M€) : 1.17 (2010), 1.15 (2009), 3.3 (2008), 1.24 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Studies
Position : Subcontractor
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .12 Licensing-in of the rights to exploit Immuno'line, a full range of services and patented technologies dedicated to Risk Assessment Immunogenicity, from Proteus LICIN [13 years]
2010 .11 Partnering research agreement with GTP Technology to combine competencies for Ab-Ag R&D [12 years]
2010 .05 Partnering research agreement with Singulex (USA) on biomarker quantification at the femtogram level to provide ultrasensitive and early biomarker detection through Erenna Immunoassay System R&D [11 years]
2009 .09 Research : launch of Gliadys project, in collaboration with IDD Biotech, based on therapeutic antibodies against different glioma forms R&D [11 years]
2008 .03 Acquisition of Axcell Biotech to strengthen OEM commercial position ACQ+ [9 years]
1998 .07 Company founded by Stéphane Legastelois ORGF [0 year]

Actualisation / Updating: 16-Mar-2012

" " * INGEN BIOSCIENCES *

 

2001 - IDF
Chilly-Mazarin
(near Paris)
www.ingen.fr

 

Design, Diagnostics
Key words: Serology, In-vitro, Biomarkers, Infectious diseases, Bacterial antigens, Microbiology, Non-invasive testing, Capucine, Abag
Mission: to design and manufacture protein biomarkers for multiparametric diagnostic in infectious diseases
Clients: Pharmaceutical industry
commercial@ingen.fr

Age: " . AGE() . " year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Buckle (Isabelle) [Ph.D. microbiology, ex-Applied Biosystems, Ciphergen Biosystems, Amersham Pharmacia Biotech]
Sc.Dir.-CSO: Mignon Godefroy (Karine) [Ph.D, ex-Chemunex, BMD, Bio-Rad]
Oper.Dir.-COO: Mollet (Patrick) [ex-Organon]
Mktg.Dir.: Martin (Jacques) [Eng. ESITPA, ex-Clonatec]
Fin.Dir.-CFO: Elorga (Esteban) [Sup-de-Co, ex-Arhur Andersen]
BusDev:
Financers (Hist.): Innoven Partners, Société Générale A.M.
Notes : Ingen website, acquired in 2006, updated with Ingen Biosciences (no company website ever as Abag) ; the company is subject of a take over in Novemebr 2012

Turnover (M€) : 0.05 (2008)
Total funding (M€) : 8.0
Last funding (M€) : 6.0
Focus : Infections
Position : Trade
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2012 .07 Partnering distribution agreement with Quidel and Diagnostic Hybrids, to sell their in vitro diagnostics in France MKTG [10 years]
2012 .06 Partnering services agreement with Eritech on project Tedac (translational medicine against cancer) R&D [10 years]
2011 .12 Acquisition of Belgian biotech company Gamma with its Tetanos Quick Stick in vitro diagnostic (through ZenTech) ACQ+ [10 years]
2010 .12 Nomination : Isabelle Buckle, new CEO, replacing Jean-Pierre Hermet (Board chairman) ORGN [9 years]
2009 .03 Company rename as InGen Biosciences (from Abag) ORGL [7 years]
2008 .12 Nomination : Jean-Pierre Hermet, new CEO ORGN [7 years]
2006 .07 Acquisition of Ingen, a distribution company founded in 1993 ACQ+ [4 years]
2006 .02 2nd round-financing : 6.0 M€, by new investor, Innoven (followed by Société Générale A.M.) RFINB [4 years]
2003 .03 1st round-financing : 2.0 M€, by Société Générale A.M. RFINA [1 year]
2001 .12 Company founded by Marc Bourlioux and Jean-Louis Gaillard, as AbAg ORGF [0 year]

Actualisation / Updating: 14-Nov-2012

" ;

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende